This website is intended for healthcare professionals
This website is intended for healthcare professionals
In 1997, Beta-interferon 1a (Avonnex) was licenced in the European Union (EU) for RRMS to reduce the impact and disease process of MS. Today there is a mixture of tablets, injections and infusions...
Natalizumab is a DMT that is used in highly active RRMS, which has a high efficacy of 70% for reducing relapses and sustaining disease progression. It is given by intravenous infusion every 4 weeks,...
Journal of Prescribing Practice shares the latest clinical expertise and professional guidance for non-medical prescribers. Our goal is to provide the knowledge to help you prescribe more efficiently and effectively.
Evidence-based best practice
Drug updates
Pharmacology information
Calculation skills